StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $29.01 | $29.39 | +1.31% | 8.4M |
| 05-13 | $29.31 | $29.22 | -0.31% | 5.7M |
| 05-14 | $29.24 | $29.50 | +0.89% | 2.9M |
| 05-15 | $29.24 | $29.29 | +0.17% | 7.2M |
| 05-18 | $29.30 | $28.96 | -1.14% | 0.3M |
| Metric | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Annual 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $5.74M | $3.74M | $2.17M | $29.05M |
Operating Income | $-930.31M | $-591.15M | $-284.92M | $-1.00B |
Net Income | $-602.76M | $-336.87M | $-223.35M | $-171.98M |
EPS (Diluted) | $-0.88 | $-0.49 | $-0.33 | $-0.24 |
Total Assets | $5.23B | $5.06B | $5.03B | $5.44B |
Total Liabilities | $251.14M | $257.14M | $216.70M | $249.74M |
Cash & Equivalents | $1.48B | $1.24B | $1.24B | $2.72B |
Free Cash Flow OCF − CapEx | $-593.48M | $-401.93M | $-208.42M | $-844.05M |
Shares Outstanding | 709.69M | 689.70M | 682.23M | 695.94M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.